BMO Capital Markets Reiterates Outperform Rating for SAGE Therapeutics (NASDAQ:SAGE)

BMO Capital Markets reaffirmed their outperform rating on shares of SAGE Therapeutics (NASDAQ:SAGE) in a research report sent to investors on Friday morning, The Fly reports. BMO Capital Markets currently has a $92.00 price objective on the biopharmaceutical company’s stock.

SAGE has been the subject of several other reports. Svb Leerink upgraded shares of SAGE Therapeutics from an underperform rating to a market perform rating in a research report on Friday. Guggenheim decreased their price target on shares of SAGE Therapeutics from $200.00 to $110.00 and set a buy rating on the stock in a research report on Thursday, December 5th. Cowen reiterated a buy rating and set a $96.00 price target on shares of SAGE Therapeutics in a research note on Thursday, December 5th. Wedbush dropped their price target on shares of SAGE Therapeutics from $203.00 to $90.00 and set an outperform rating on the stock in a research note on Thursday, December 5th. Finally, Stifel Nicolaus reissued a buy rating on shares of SAGE Therapeutics in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $128.81.

SAGE Therapeutics stock opened at $62.66 on Friday. The business has a 50-day simple moving average of $137.72 and a two-hundred day simple moving average of $159.26. The company has a market cap of $3.34 billion, a P/E ratio of -7.75 and a beta of 2.52. SAGE Therapeutics has a 52-week low of $56.50 and a 52-week high of $193.56. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.41) by ($0.07). The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. SAGE Therapeutics’s revenue for the quarter was up 35600.0% on a year-over-year basis. During the same quarter last year, the company earned ($2.63) EPS. Research analysts anticipate that SAGE Therapeutics will post -13.77 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. increased its stake in shares of SAGE Therapeutics by 40.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock worth $21,704,000 after purchasing an additional 39,447 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of SAGE Therapeutics by 4.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 77 shares during the period. Creative Planning lifted its stake in shares of SAGE Therapeutics by 13.0% during the 2nd quarter. Creative Planning now owns 2,563 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 294 shares in the last quarter. Janney Capital Management LLC lifted its stake in shares of SAGE Therapeutics by 18.2% during the 2nd quarter. Janney Capital Management LLC now owns 4,387 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 675 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in shares of SAGE Therapeutics by 5.0% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $834,000 after buying an additional 219 shares in the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Recommended Story: Trading based on a resistance level

The Fly

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.